Gene delivery to overcome astrocyte inhibition of axonal growth: an in vitro model of the glial scar.
After injury to the central nervous system, a glial scar develops that physically and biochemically inhibits axon growth. In the scar, activated astrocytes secrete inhibitory extracellular matrix, of which chondroitin sulfate proteoglycans (CSPGs) are considered the major inhibitory component. An inhibitory interface of CSPGs forms around the lesion and prevents axons from traversing the injury, and decreasing CSPGs can enhance axon growth. In this report, we established an in vitro interface model of activated astrocytes and subsequently investigated gene delivery as a means to reduce CSPG levels and enhance axon growth. In the model, a continuous interface of CSPG producing astrocytes was created with neurons seeded opposite the astrocytes, and neurite crossing, stopping, and turning were evaluated as they approached the interface. We investigated the efficacy of lentiviral delivery to degrade or prevent the synthesis of CSPGs, thereby removing CSPG inhibition of neurite growth. Lentiviral delivery of RNAi targeting two key CSPG synthesis enzymes, chondroitin polymerizing factor and chondroitin synthase-1, decreased CSPGs, and reduced inhibition by the interface. Degradation of CSPGs by lentiviral delivery of chondroitinase also resulted in less inhibition and more neurites crossing the interface. These results indicate that the interface model provides a tool to investigate interventions that reduce inhibition by CSPGs, and that gene delivery can be effective in promoting neurite growth across an interface of CSPG producing astrocytes.
Department of Chemical and Biological Engineering, Northwestern University, Evanston, Illinois 60208, USA.
Hannah M
HM
Tuinstra
Melissa M
MM
Ducommun
William E
WE
Briley
Lonnie D
LD
Shea
D000818:Animals; D001253:Astrocytes / Q000502:physiology*; D002460:Cell Line; D011508:Chondroitin Sulfate Proteoglycans / Q000037:antagonists & inhibitors*; D002810:Chondroitinases and Chondroitin Lyases / Q000378:metabolism; D002921:Cicatrix / Q000503:physiopathology*; D020868:Gene Silencing; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D016086:Lentivirus / Q000201:enzymology / Q000235:genetics; D008962:Models, Theoretical; D009474:Neurons / Q000502:physiology*; D034741:RNA, Small Interfering / Q000235:genetics; D051381:Rats; D014161:Transduction, Genetic; D014170:Transformation, Genetic
D011508:Chondroitin Sulfate Proteoglycans; D034741:RNA, Small Interfering; D002810:Chondroitinases and Chondroitin Lyases